Skip to main content
Article

Protein predicts risk of AKI in COVID-19 patients

Levels of a specific protein Soluble urokinase plasminogen activator receptor (suPAR) produced by immune cells predicts a very high risk of AKI. Median suPAR level 60% higher in patients with vs without AKI.

The current analysis involved 352 patients with COVID-19 who had a mean estimated glomerular filtration rate (eGFR) of 80 mL/min/1.73m2 at admission.

suPAR was measured in plasma using a commercially available ELISA (suPARnostic assay by ViroGates).

Leave a Reply

error: